For the year ending 2025-12-31, ZBIO made $10M in revenue. -$377.995M in net income. Net profit margin of -3779.95%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 10 | |||
| Research and development | 168.063 | |||
| General and administrative | 53.322 | |||
| Acquired in-process research and development | 171.672 | |||
| Total operating expenses | 393.057 | |||
| Loss from operations | -383.057 | |||
| Interest expense on royalty obligation | 7.327 | |||
| Interest income | 12.151 | |||
| Other income, net | 0.417 | |||
| Total other income (expense), net | 5.241 | |||
| Loss before income taxes | -377.816 | |||
| Income tax (benefit) provision | -0.079 | |||
| Net loss | -377.737 | |||
| Unrealized gain on investments | 0.156 | |||
| Foreign currency translation adjustment | -0.414 | |||
| Comprehensive loss | -377.995 | |||
| Basic EPS | -8.44 | |||
| Diluted EPS | -8.44 | |||
| Basic Average Shares | 44,730,052 | |||
| Diluted Average Shares | 44,730,052 | |||
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)